CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The company made meaningful advances across multiple clinical and preclinical programs including encouraging data from zugo-cel in autoimmune disease and oncology

  80% confidence

• Company expects to provide update on CTX611 in second half of 2026

  80% confidence

• Approximately 90% of patients in U.S. have reimbursed access to CASGEVY as of year-end 2025

  80% confidence

• Company expects to initiate clinical trial for CTX340 in first half of 2026

  80% confidence

• CTX321 incorporates updated guide RNA demonstrating approximately two-fold greater potency in preclinical testing compared to CTX320

  80% confidence

• CTX611 program has potential to target multi-billion-dollar market opportunity including atrial fibrillation, venous thromboembolism, ischemic stroke, and other indications

  80% confidence

• Patient initiations and first cell collections increased nearly three-fold in 2025 compared to 2024

  80% confidence

• Company expects to initiate clinical trial for CTX460 in mid-2026

  80% confidence

• Company expects to provide update on CTX310 in second half of 2026

  80% confidence

• CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline

  80% confidence

• Global regulatory submissions for CASGEVY in children ages 5-11 expected to begin in first half of 2026

  80% confidence

• Company expects to provide updates on zugo-cel in autoimmune disease and immuno-oncology in second half of 2026

  80% confidence

Cited in these Via News reports

• Gene Therapy, mRNA and CRISPR: The Global Biotech Boom Reshaping How the World Finances Medicine →